Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 402

 

Home  | About Us | Editors | Search | Ahead Of Print | Current Issue | Archives | Submit Article | Instructions | Subscribe | Contacts | Login 
     


 
 
Table of Contents
EDITORIAL
Year : 2016  |  Volume : 6  |  Issue : 4  |  Page : 161-162

What's New in Critical Illness and Injury Science? Coagulants for local application in the surgical armamentarium!


Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India

Date of Web Publication8-Dec-2016

Correspondence Address:
Shilpa Sharma
Department of Pediatric Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-5151.195388

Rights and Permissions

How to cite this article:
Sharma S. What's New in Critical Illness and Injury Science? Coagulants for local application in the surgical armamentarium!. Int J Crit Illn Inj Sci 2016;6:161-2

How to cite this URL:
Sharma S. What's New in Critical Illness and Injury Science? Coagulants for local application in the surgical armamentarium!. Int J Crit Illn Inj Sci [serial online] 2016 [cited 2017 Nov 23];6:161-2. Available from: http://www.ijciis.org/text.asp?2016/6/4/161/195388

Dear Editor,

Coagulants form an important part of surgical hemostasis, especially during liver resection. This issue of the journal has an interesting article, "Comparison of the haemostatic effects of Ankaferd blood stopper (ABS), oxidised cellulose and calcium alginate in an experimental animal model of liver parenchyma bleeding." The process of coagulation along with the various available agents is discussed here with regard to their safety, composition, hemostatic and biodegradable properties.

There are often times when after attaining hemostasis after a major liver resection, there is persistent oozing from the surface uncontrolled with pressure, ligature, or electrocautery. Coagulation, the process by which blood changes from a liquid to gel, forming a clot results in hemostasis. Platelet activation by the tissue factor is the first initiation step for the coagulation cascade. Local application of hemostats act as tissue factors and stop capillary, venous, and arteriolar bleeding effectively when conventional methods are either ineffective or impractical [Figure 1].
Figure 1: Coagulants act as tissue factors and promote platelet aggregation

Click here to view


The most commonly used products have been the Gelfoam ® /Spongostan gelatinized sponge and the Surgicel ® (oxidized cellulose). They provide a strong matrix for platelet adhesion and aggregation, accelerating the formation of a platelet plug and acting as a catalyst in forming a fibrin clot. The other less commonly used agents include thrombin, calcium alginate, and collagen.

Gelatin sponge is an off-white, water-insoluble, porous, malleable, porcine gelatin absorbable sponge. It can be used dry or saturated with the saline solution, with or without the addition of thrombin.

Oxidized cellulose is a water-insoluble derivative of cellulose produced by the action of an oxidizing agent, such as chlorine, hydrogen peroxide, peracetic acid, chlorine dioxide, nitrogen dioxide, persulfates, permanganate, dichromate-sulfuric acid, hypochlorous acid, hypohalites, or periodates and a variety of metal catalysts. Oxidized cellulose may contain carboxylic acid, aldehyde, and/or ketone groups, depending on the nature of the oxidant and reaction conditions. Oxidized cellulose products generally turn into a gelatinous mass in contact with the fluid and disaggregate. Surgicel ® Fibrillar absorbable hemostat is lightweight, versatile, and its easily separable layers conform and tufts peel off as little or as much as desired. It has 33% faster hemostasis compared to surgicel. It has proven bactericidal properties. Gelita-Cel ® is a natural hemostat made of biodegradable 100% organic oxidized cellulose extracted from natural alpha grade cotton with hollow fibers and greater capacity to absorb oxidizing agents, greater instability, and enhanced biodegradability. Its low pH causes localized vasoconstriction, further enhancing the hemostatic effect. In addition, the low pH exhibits antibacterial properties, minimizing the risk of infection. Gelita-Cel ® is stable ensuring easy handling and repositioning on the wound as needed and completely biodegradable in <4 weeks with reduced risk of encapsulation.

Calcium alginate is a water-insoluble, gelatinous, cream-colored substance that can be created through the addition of aqueous calcium chloride to aqueous sodium alginate extracted from seaweed, broken into pieces and stirred with a hot solution of an alkali, usually sodium carbonate. It is also incorporated into wound dressings as a hemostatic agent.

Avitene Microfibrillar collagen is an active absorbable collagen hemostat, proven to accelerate clot formation by enhancing platelet aggregation and release of proteins to form fibrin, resulting in hemostasis. Gauze soaked in epinephrine/adrenaline has also been used to reduce surgical bleeding. Botropase available in injection form is composed of hemocoagulase. It contains batroxobin, a hemostatic agent, a thrombin-like enzyme, obtained from the venom of the serpent Bothrops atrox. The Tisseel ® tissue glue, a fibrin sealant, is a relatively new addendum but is expensive and not readily available.

ABS, a novel coagulant agent, has demonstrated promising results in various sources of bleeding. ABS is a Turkish herbal product comprising five plants: Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica, developed by Hüseyin Cahit Firat, the first Turkish medical product officially accredited by the Turkish Ministry of Health. [1],[2] It is used in hospitals and ambulances in Turkey to stop bleeding from external bodily injuries and operations due to its antihemorrhagic properties. Goker et al. demonstrated that when ABS is added to plasma or serum, it induces a rapid formation of a protein network and erythrocyte aggregation without affecting the levels of coagulation factors such as II, V, VII, VIII, IX, X, XI, and XIII. [1] Plasma fibrinogen activity and antigen levels were decreased along with prolonged thrombin time. [1] Total protein, albumin, and globulin levels decreased after the addition of ABS. These findings suggested that ABS stimulated the formation of an encapsulated protein network that provides focal points for erythrocyte aggregation, thus possessing antihemorrhagic potential.

ABS has been used to control gastrointestinal, variceal bleeding, presacral bleeding, and epistaxis. [3],[4],[5],[6] While some authors have found it to be as effective as Surgicel ® in controlling bleeding from liver laceration, others have demonstrated superior results. [7],[8] Livers with ABS application completed their regeneration process with minimal signs of inflammation as demonstrated on histopathology and better intra-abdominal adhesion scores. [8]

 
   References Top

1.
Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper®. J Int Med Res 2008;36:163-70.  Back to cited text no. 1
    
2.
Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010;15:329-36.  Back to cited text no. 2
    
3.
Gungor G, Goktepe MH, Biyik M, Polat I, Tuna T, Ataseven H, et al. Efficacy of ankaferd blood stopper application on non-variceal upper gastrointestinal bleeding. World J Gastrointest Endosc 2012;4:556-60.  Back to cited text no. 3
    
4.
Okten S, Kurt M, Onal IK, Haznedaroglu IC. Use of Ankaferd Blood Stopper for controlling actively bleeding fundal varices. Singapore Med J 2011;52:e11-2.  Back to cited text no. 4
    
5.
Karaman K, Bostanci EB, Ercan M, Kurt M, Teke Z, Reyhan E, et al. Topical Ankaferd application to presacral bleeding due to total mesorectal excision in rectal carcinoma. J Invest Surg 2010;23:175.  Back to cited text no. 5
    
6.
Meric Teker A, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010;267:1377-81.  Back to cited text no. 6
    
7.
Karakaya K, Ucan HB, Tascilar O, Emre AU, Cakmak GK, Irkorucu O, et al. Evaluation of a new hemostatic agent Ankaferd Blood Stopper in experimental liver laceration. J Invest Surg 2009;22:201-6.  Back to cited text no. 7
    
8.
Satar NY, Akkoc A, Oktay A, Topal A, Inan K. Evaluation of the hemostatic and histopathological effects of Ankaferd Blood Stopper in experimental liver injury in rats. Blood Coagul Fibrinolysis 2013;24:518-24.  Back to cited text no. 8
    


    Figures

  [Figure 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed658    
    Printed9    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal